Sodium–glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) such as empagliflozin (EMPA) are currently part of therapy for patients with heart failure (HF) due to their cardioprotective effects [7]. This evidence concerns the gene SLC5A2 and hydrops fetalis.